Utility of SARS-CoV-2 Subgenomic RNA in Kidney Transplant Recipients Receiving Remdesivir.
Dynamics of subgenomic RNA
Kidney transplant recipients
Monitor virological response
SARS-CoV-2
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
24 May 2024
24 May 2024
Historique:
received:
29
01
2024
accepted:
06
05
2024
medline:
25
5
2024
pubmed:
25
5
2024
entrez:
24
5
2024
Statut:
aheadofprint
Résumé
There is no reliable microbiological marker to guide responses to antiviral treatment in kidney transplant recipients (KTR) with COVID-19. We aimed to evaluate the dynamics of subgenomic RNA (sgRNA) RT-PCR before and after receiving treatment with remdesivir compared with genomic RNA (gRNA) RT-PCR and its use as a surrogate marker of viral replication. We analyzed gRNA and sgRNA at baseline and after remdesivir treatment in KTR who received remdesivir for SARS-CoV-2 infection from November 2021 to February 2022. Thirty-four KTR received remdesivir for SARS-CoV-2 infection. The median time since transplantation was 80 months (IQR 3-321) and 75% of patients had previously received 3 doses of a mRNA SARS-CoV-2 vaccine. Three patients (8%) were classified with mild, 25 (73%) with moderate, and 6 (17%) with severe SARS-CoV-2 infection. Thirty-two (94%) patients received 5 doses of remdesivir and two patients received 2 doses. The median time between symptom onset to remdesivir treatment was 5 days (IQR 3-8.5). The median days of hospitalization were 6 (IQR 2-112). gRNA was positive in all patients at baseline and after remdesivir. Five (15%) patients had negative sgRNA at baseline and 20 (59%) after receiving remdesivir. Patients presenting with negative sgRNA at baseline were discharged from hospital in ≤ 6 days without complications. Moreover, those with negative sgRNA after remdesivir therapy did not require ICU admission and had favorable outcomes. Nevertheless, patients with positive sgRNA after antiviral treatment presented worse outcomes, with 47% requiring ICU admission and the three (9%) recorded deaths in the study were in this group. Based on these data, we hypothesize that sgRNA may have clinical utility to help monitor virologic response more accurately than gRNA in KTR who receive remdesivir. Moreover, patients with negative sgRNA at baseline may not require antiviral treatment and others presenting positive sgRNA at day 5 could benefit from prolonged or combined therapies.
Identifiants
pubmed: 38789902
doi: 10.1007/s40121-024-00991-6
pii: 10.1007/s40121-024-00991-6
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
World Health Organization. COVID-19 Epidemiological update. Emergency Situational Updates, p. Edition 161 COVID-19 Epidemiological update—(24 November 2023). Edition 161. Emergency Situational Updates. 2023. Available from: https://www.who.int/publications/m/item/covid-19-epidemiological-update-24-november-2023 . [cited 2024 Jan 10]
Caillard S, Chavarot N, Francois H, Matignon M, Greze C, Kamar N, et al. Is COVID-19 infection more severe in kidney transplant recipients? Am J Transplant. 2021;21(3):1295–303.
doi: 10.1111/ajt.16424
pubmed: 33259686
Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med [Internet]. 2020;383(23):2291–3. Available from: https://pubmed.ncbi.nlm.nih.gov/33176080/ . [cited 2023 May 30]
Niess H, Börner N, Muenchhoff M, Khatamzas E, Stangl M, Graf A, et al. Liver transplantation in a patient after COVID-19—rapid loss of antibodies and prolonged viral RNA shedding. Am J Transplant [Internet]. 2021;21(4):1629–32. Available from: https://pubmed.ncbi.nlm.nih.gov/33047475/ . [cited 2023 May 30]
Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol. 2022.
Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198: 105252.
doi: 10.1016/j.antiviral.2022.105252
pubmed: 35085683
pmcid: 8785409
Arch B KDSJ et al. Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study. Medrxiv. 2021.
Gandhi S, Klein J, Robertson AJ, Peña-Hernández MA, Lin MJ, Roychoudhury P, et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun [Internet]. 2022;13(1). Available from: https://pubmed.ncbi.nlm.nih.gov/35301314/ . [cited 2023 May 30]
Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824):273–6.
doi: 10.1038/s41586-020-2423-5
pubmed: 32516797
pmcid: 7486271
Garcia-Vidal C, Alonso R, Camon AM, Cardozo C, Albiach L, Agüero D, et al. Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. J Antimicrob Chemother. 2021;76(12):3296–302.
doi: 10.1093/jac/dkab321
pubmed: 34473275
Marrone A, Nevola R, Sellitto A, Cozzolino D, Romano C, Cuomo G, et al. Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of coronavirus disease 2019 (COVID-19) patients requiring supplemental O2 therapy: a prospective controlled nonrandomized study. Clin Infect Dis [Internet]. 2022;75(1):E403–9. Available from: https://pubmed.ncbi.nlm.nih.gov/35084022/ . [cited 2023 May 30]
Hierholzer JC, Killington RA. Virus isolation and quantitation. Virol Methods Manual. 1996;1:25–46.
doi: 10.1016/B978-012465330-6/50003-8
Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–9.
doi: 10.1038/s41586-020-2196-x
pubmed: 32235945
Wu HY, Brian DA. Subgenomic messenger RNA amplification in coronaviruses. Proc Natl Acad Sci. 2010;107(27):12257–62.
doi: 10.1073/pnas.1000378107
pubmed: 20562343
pmcid: 2901459
Santos Bravo M, Berengua C, Marín P, Esteban M, Rodriguez C, del Cuerpo M, et al. Viral culture confirmed SARS-CoV-2 subgenomic RNA value as a good surrogate marker of infectivity. 2022. https://doi.org/10.6084/m9.figshare.16802200.v1
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045
doi: 10.2807/1560-7917.ES.2020.25.3.2000045
pubmed: 31992387
pmcid: 6988269
Alonso-navarro R, Cuesta G, Santos M, Cardozo C, Rico V, Garcia-pouton N, et al. Qualitative subgenomic RNA to monitor the response to remdesivir in hospitalized patients with COVID-19: impact on the length of hospital stay 2 and mortality. Available from: https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model .
Moreno G, Rodríguez A, Reyes LF, Gomez J, Sole-Violan J, Díaz E, et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med [Internet]. 2018;44(9):1470–82. Available from: https://pubmed.ncbi.nlm.nih.gov/30074052/ . [Cited 2023 May 30].
Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F, et al. Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients. Clin Infect Dis [Internet]. 2023; Available from: https://pubmed.ncbi.nlm.nih.gov/36976301/ . [Cited 2023 May 30].
Binnicker MJ. Can testing predict SARS-CoV-2 infectivity? the potential for certain methods to be surrogates for replication-competent virus. J Clin Microbiol. 2021;59(11):e0046921. https://doi.org/10.1128/JCM.00469-21
doi: 10.1128/JCM.00469-21
pubmed: 34346713
Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. Nat Commun [Internet]. 2020;11(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33247099/ . [Cited 2023 May 30].